<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31745214</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5403</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Cell death and differentiation</Title><ISOAbbreviation>Cell Death Differ</ISOAbbreviation></Journal><ArticleTitle>Necroptosis is dispensable for motor neuron degeneration in a mouse model of ALS.</ArticleTitle><Pagination><StartPage>1728</StartPage><EndPage>1739</EndPage><MedlinePgn>1728-1739</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41418-019-0457-8</ELocationID><Abstract><AbstractText>Motor neuron degeneration in amyotrophic lateral sclerosis (ALS) is proposed to occur by necroptosis, an inflammatory form of regulated cell death. Prior studies implicated necroptosis in ALS based on accumulation of necroptotic markers in affected tissues of patients and mouse models, and amelioration of disease in mutant superoxide dismutase 1 (SOD1<sup>G93A</sup>) mice with inhibition of the upstream necroptotic mediators, receptor interacting protein kinase 1 (RIPK1), and RIPK3. To definitively address the pathogenic role of necroptosis in ALS, we genetically ablated the critical terminal executioner of necroptosis, mixed lineage kinase domain-like protein (MLKL), in SOD1<sup>G93A</sup> mice. Disease onset, progression, and survival were not affected in SOD1<sup>G93A</sup> mice lacking MLKL. Motor neuron degeneration and activation of neuroinflammatory cells, astrocytes, and microglia, were independent of MLKL expression in SOD1<sup>G93A</sup> mice. While RIPK1 accumulation occurred in spinal cords of SOD1<sup>G93A</sup> mice in late stage disease, RIPK3 and MLKL expression levels were not detected in central nervous system tissues from normal or SOD1<sup>G93A</sup> mice at any disease stage. These findings demonstrate that necroptosis does not play an important role in motor neuron death in ALS, which may limit the potential of therapeutic targeting of necroptosis in the treatment of neurological disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Taide</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perera</LastName><ForeName>Nirma D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiam</LastName><ForeName>Mathew D F</ForeName><Initials>MDF</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuic</LastName><ForeName>Brittany</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wanniarachchillage</LastName><ForeName>Nayomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomas</LastName><ForeName>Doris</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samson</LastName><ForeName>Andr&#xe9; L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0002-0637-2716</Identifier><AffiliationInfo><Affiliation>The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biology, University of Melbourne, Parkville, VIC, 3050, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cawthorne</LastName><ForeName>Wayne</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valor</LastName><ForeName>Eric N</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>SciOpen Research Group, Aptos, CA, 95003, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>James M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-0195-3949</Identifier><AffiliationInfo><Affiliation>The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biology, University of Melbourne, Parkville, VIC, 3050, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Bradley J</ForeName><Initials>BJ</Initials><Identifier Source="ORCID">0000-0001-6580-7655</Identifier><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, 3010, Australia. bradley.turner@florey.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cell Death Differ</MedlineTA><NlmUniqueID>9437445</NlmUniqueID><ISSNLinking>1350-9047</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="C570694">MLKL protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D053422">Receptor-Interacting Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C506251">Ripk1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000079302" MajorTopicYN="Y">Necroptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053422" MajorTopicYN="N">Receptor-Interacting Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>JMM contributes to a program developing inhibitors of necroptosis with Anaxis Pharma Pty Ltd. The other authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31745214</ArticleId><ArticleId IdType="pmc">PMC7206015</ArticleId><ArticleId IdType="doi">10.1038/s41418-019-0457-8</ArticleId><ArticleId IdType="pii">10.1038/s41418-019-0457-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner BJ, Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol. 2008;85:94&#x2013;134. doi: 10.1016/j.pneurobio.2008.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2008.01.001</ArticleId><ArticleId IdType="pubmed">18282652</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008;11:251&#x2013;3. doi: 10.1038/nn2047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2047</ArticleId><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci. 2007;10:608&#x2013;14. doi: 10.1038/nn1885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1885</ArticleId><ArticleId IdType="pmc">PMC3139463</ArticleId><ArticleId IdType="pubmed">17435754</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10:615&#x2013;22. doi: 10.1038/nn1876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1876</ArticleId><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio FP, Boulting GL, Bobrowicz S, Eggan KC. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell. 2008;3:637&#x2013;48. doi: 10.1016/j.stem.2008.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2008.09.017</ArticleId><ArticleId IdType="pubmed">19041780</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetto MCN, Muotri AR, Mu Y, Smith AM, Cezar GG, Gage FH. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell. 2008;3:649&#x2013;57. doi: 10.1016/j.stem.2008.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2008.10.001</ArticleId><ArticleId IdType="pubmed">19041781</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A, et al. Astrocytes from familial and sporadic als patients are toxic to motor neurons. Nat Biotechnol. 2012;29:824&#x2013;8. doi: 10.1038/nbt.1957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1957</ArticleId><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Re DB, Le Verche V, Yu C, Amoroso MW, Politi KA, Phani S, et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron. 2014;81:1001&#x2013;8. doi: 10.1016/j.neuron.2014.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.011</ArticleId><ArticleId IdType="pmc">PMC3951532</ArticleId><ArticleId IdType="pubmed">24508385</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould TW. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J Neurosci. 2006;26:8774&#x2013;86. doi: 10.1523/JNEUROSCI.2315-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2315-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674380</ArticleId><ArticleId IdType="pubmed">16928866</ArticleId></ArticleIdList></Reference><Reference><Citation>Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2000;1:489&#x2013;485. doi: 10.1038/82732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/82732</ArticleId><ArticleId IdType="pubmed">11101870</ArticleId></ArticleIdList></Reference><Reference><Citation>Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1:112&#x2013;9. doi: 10.1038/nchembio711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio711</ArticleId><ArticleId IdType="pubmed">16408008</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton K, Dugger DL, Wickliffe KE, Kapoor N, De Almagro MC, Vucic D, et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science. 2014;343:1357&#x2013;60. doi: 10.1126/science.1249361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1249361</ArticleId><ArticleId IdType="pubmed">24557836</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang JG, Alvarez-Diaz S, et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity. 2013;39:443&#x2013;53. doi: 10.1016/j.immuni.2013.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.06.018</ArticleId><ArticleId IdType="pubmed">24012422</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Huang Z, Ren J, Zhang Z, He P, Li Y, et al. Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. Cell Res. 2013;23:994&#x2013;1006. doi: 10.1038/cr.2013.91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2013.91</ArticleId><ArticleId IdType="pmc">PMC3731568</ArticleId><ArticleId IdType="pubmed">23835476</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton K, Sun X, Dixit VM. Kinase RIP3 Is dispensable for normal NF- Bs, signaling by the B-Cell and T-Cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol Cell Biol. 2004;24:1464&#x2013;9. doi: 10.1128/MCB.24.4.1464-1469.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.24.4.1464-1469.2004</ArticleId><ArticleId IdType="pmc">PMC344190</ArticleId><ArticleId IdType="pubmed">14749364</ArticleId></ArticleIdList></Reference><Reference><Citation>Hildebrand JM, Tanzer MC, Lucet IS, Young SN, Spall SK, Sharma P, et al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proc Natl Acad Sci. 2014;111:15072&#x2013;7. doi: 10.1073/pnas.1408987111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1408987111</ArticleId><ArticleId IdType="pmc">PMC4210347</ArticleId><ArticleId IdType="pubmed">25288762</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzer MC, Matti I, Hildebrand JM, Young SN, Wardak A, Tripaydonis A, et al. Evolutionary divergence of the necroptosis effector MLKL. Cell Death Differ. 2016;23:1185&#x2013;97. doi: 10.1038/cdd.2015.169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2015.169</ArticleId><ArticleId IdType="pmc">PMC4946887</ArticleId><ArticleId IdType="pubmed">26868910</ArticleId></ArticleIdList></Reference><Reference><Citation>Dondelinger Y, Declercq W, Montessuit S, Roelandt R, Goncalves A, Bruggeman I, et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep. 2014;7:971&#x2013;81. doi: 10.1016/j.celrep.2014.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.04.026</ArticleId><ArticleId IdType="pubmed">24813885</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Li W, Ren J, Huang D, He WT, Song Y, et al. Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. Cell Res. 2014;24:105&#x2013;21. doi: 10.1038/cr.2013.171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2013.171</ArticleId><ArticleId IdType="pmc">PMC3879712</ArticleId><ArticleId IdType="pubmed">24366341</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrie EJ, Sandow JJ, Jacobsen AV, Smith BJ, Griffin MDW, Lucet IS, et al. Conformational switching of the pseudokinase domain promotes human MLKL tetramerization and cell death by necroptosis. Nat Commun. 2018;9:2442. doi: 10.1038/s41467-018-04714-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04714-7</ArticleId><ArticleId IdType="pmc">PMC6013482</ArticleId><ArticleId IdType="pubmed">29930286</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Sun L, Su L, Rizo J, Liu L, Wang LF, et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell. 2014;54:133&#x2013;46. doi: 10.1016/j.molcel.2014.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2014.03.003</ArticleId><ArticleId IdType="pubmed">24703947</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrie EJ, Czabotar PE, Murphy JM. The Structural Basis of Necroptotic Cell Death Signaling. Trends Biochem Sci. 2019;44:53&#x2013;63. doi: 10.1016/j.tibs.2018.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2018.11.002</ArticleId><ArticleId IdType="pubmed">30509860</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, Ofengeim D, Najafov A, Das S, Saberi S, Li Y, et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science. 2016;353:603&#x2013;8. doi: 10.1126/science.aaf6803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf6803</ArticleId><ArticleId IdType="pmc">PMC5444917</ArticleId><ArticleId IdType="pubmed">27493188</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger SB, Kasparcova V, Hoffman S, Swift B, Dare L, Schaeffer M, et al. Cutting edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J Immunol. 2014;192:5476&#x2013;80. doi: 10.4049/jimmunol.1400499.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1400499</ArticleId><ArticleId IdType="pmc">PMC4048763</ArticleId><ArticleId IdType="pubmed">24821972</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukens JR, Vogel P, Johnson GR, Kelliher MA, Iwakura Y, Lamkanfi M, et al. RIP1-driven autoinflammation targets IL-1&#x3b1; independently of inflammasomes and RIP3. Nature. 2013;498:224&#x2013;7. doi: 10.1038/nature12174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12174</ArticleId><ArticleId IdType="pmc">PMC3683390</ArticleId><ArticleId IdType="pubmed">23708968</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong WWL, Vince JE, Lalaoui N, Lawlor KE, Chau D, Bankovacki A, et al. cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- And RIPK3-dependent manner. Blood. 2014;123:2562&#x2013;72. doi: 10.1182/blood-2013-06-510743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-06-510743</ArticleId><ArticleId IdType="pubmed">24497535</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Diaz S, Dillon CP, Lalaoui N, Tanzer MC, Rodriguez DA, Lin A, et al. The pseudokinase MLKL and the kinase RIPK3 have distinct roles in autoimmune disease caused by loss of death-receptor-induced apoptosis. Immunity. 2016;45:513&#x2013;26. doi: 10.1016/j.immuni.2016.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.07.016</ArticleId><ArticleId IdType="pmc">PMC5040700</ArticleId><ArticleId IdType="pubmed">27523270</ArticleId></ArticleIdList></Reference><Reference><Citation>Najjar M, Saleh D, Zelic M, Nogusa S, Shah S, Tai A, et al. RIPK1 and RIPK3 kinases promote cell-death-independent inflammation by Toll-like receptor 4. Immunity. 2016;45:46&#x2013;59. doi: 10.1016/j.immuni.2016.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.06.007</ArticleId><ArticleId IdType="pmc">PMC4956514</ArticleId><ArticleId IdType="pubmed">27396959</ArticleId></ArticleIdList></Reference><Reference><Citation>Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, et al. CIAPs block ripoptosome formation, a RIP1/Caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell. 2011;43:449&#x2013;63. doi: 10.1016/j.molcel.2011.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2011.06.011</ArticleId><ArticleId IdType="pmc">PMC3163271</ArticleId><ArticleId IdType="pubmed">21737330</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook WD, Moujalled DM, Ralph TJ, Lock P, Young SN, Murphy JM, et al. RIPK1-and RIPK3-induced cell death mode is determined by target availability. Cell Death Differ. 2014;21:1600&#x2013;12. doi: 10.1038/cdd.2014.70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2014.70</ArticleId><ArticleId IdType="pmc">PMC4158685</ArticleId><ArticleId IdType="pubmed">24902899</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Wang H, Wang Z, He S, Chen S, Liao D, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148:213&#x2013;27. doi: 10.1016/j.cell.2011.11.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.11.031</ArticleId><ArticleId IdType="pubmed">22265413</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J, et al. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc Natl Acad Sci USA. 2012;104:5322&#x2013;7. doi: 10.1073/pnas.1200012109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1200012109</ArticleId><ArticleId IdType="pmc">PMC3325682</ArticleId><ArticleId IdType="pubmed">22421439</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera ND, Sheean RK, Lau CL, Shin YS, Beart PM, Horne MK, et al. Rilmenidine promotes MTOR-independent autophagy in the mutant SOD1 mouse model of amyotrophic lateral sclerosis without slowing disease progression. Autophagy. 2018;14:548. doi: 10.1080/15548627.2017.1385674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2017.1385674</ArticleId><ArticleId IdType="pmc">PMC5915012</ArticleId><ArticleId IdType="pubmed">28980850</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrie EJ, Sandow JJ, Lehmann WIL, Liang L-Y, Coursier D, Young SN, et al. Viral MLKL homologs subvert necroptotic cell death by sequestering cellular RIPK3. Cell Rep. 2019;28:3309&#x2013;19. doi: 10.1016/j.celrep.2019.08.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.08.055</ArticleId><ArticleId IdType="pubmed">31553902</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermentzaki G, Politi KA, Lu L, Mishra V, P&#xe9;rez-Torres EJ, Sosunov AA, et al. Deletion of Ripk3 prevents motor neuron death in vitro but not in vivo. Eneuro. 2019;6:E-Collection. 10.1523/ENEURO.0308-18.2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6391588</ArticleId><ArticleId IdType="pubmed">30815534</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Branca C, Piras IS, Ferreira E, Huentelman MJ, Liang WS, et al. Necroptosis activation in Alzheimer&#x2019;s disease. Nat Neurosci. 2017;20:1236&#x2013;46. doi: 10.1038/nn.4608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4608</ArticleId><ArticleId IdType="pubmed">28758999</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofengeim D, Ito Y, Najafov A, Zhang Y, Shan B, DeWitt JP, et al. Activation of necroptosis in multiple sclerosis. Cell Rep. 2015;10:1836&#x2013;49. doi: 10.1016/j.celrep.2015.02.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.02.051</ArticleId><ArticleId IdType="pmc">PMC4494996</ArticleId><ArticleId IdType="pubmed">25801023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-&#x3ba;B signal. Immunity. 1998;8:297&#x2013;303. doi: 10.1016/S1074-7613(00)80535-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(00)80535-X</ArticleId><ArticleId IdType="pubmed">9529147</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, Duhadaway JB, et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis. 2012;3:e437&#x2013;10. doi: 10.1038/cddis.2012.176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2012.176</ArticleId><ArticleId IdType="pmc">PMC3542611</ArticleId><ArticleId IdType="pubmed">23190609</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa D, Desai J, Steiger S, M&#xfc;ller S, Devarapu SK, Mulay SR, et al. Activated platelets induce MLKL-driven neutrophil necroptosis and release of neutrophil extracellular traps in venous thrombosis. Cell Death Discov. 2018;4:eCollection 10.1038/s41420-018-0073-2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6060161</ArticleId><ArticleId IdType="pubmed">30062055</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>